Physician profile
Robert H Kneece
NPI 1902823545
$1,598.28
in general payments reported to CMS, 2019-2025
20 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $311 · 2023: $645 · 2024: $393 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $268.91 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $262.86 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $167.48 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $125.33 | 2023-2024 | |
| Abbott Laboratories | $121.36 | 2022-2023 | Freestyle Libre 3 |
| Pfizer INC. | $109.94 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.36 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.59 | 2022-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $69.09 | 2022-2025 | |
| Amgen INC. | $48.69 | 2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $40.94 | 2022-2023 | |
| Exact Sciences Corporation | $40.21 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $34.23 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $32.56 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.46 | 2024 | Trulance, Xifaxan |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $21.59 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.75 | 2024 | Gvoke Hypopen |
| Alnylam Pharmaceuticals INC. | $18.19 | 2023 | Onpattro |
| Phathom Pharmaceuticals, INC. | $13.61 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kneece listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.